Researchers Database

ueda masuzu

    Dept.ofRegionalCooperativeService Assistant Professor
Last Updated :2021/11/23

Researcher Information


J-Global ID

Research Interests

  • 骨髄内移植   慢性肉芽腫症   遺伝子治療   選択的増幅遺伝子   造血幹細胞移植   

Research Areas

  • Life sciences / Hematology and oncology


  • Miyuki Sasazaki, Masaki Mori, Mituyo Uesawa, Shinitirou Fuziwara, Yuuzi Kikuti, Kazuya Satou, Tomohiro Matuyama, Ken Oomine, Masuzu Ueda, Takahiro Suzuki, Katutosi Ozaki, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa  Jichi Medical University journal  33-  23  -28  2011/03  [Not refereed][Not invited]
    Burkitt lymphoma/leukemia (BL) was formerly recognized as an aggressive malignant lymphoma with a poor prognosis. To confirm whether the prognosis of BL is improved by the Hyper-CVAD/HD-MTX/Ara-C regimen with or without rituximab (group B) compared with the classical treatment regimen for acute lymphoblastic leukemia or non-Hodgkin lymphoma (group A), the outcomes of 10 patients treated in our hospital from 1997 to 2009 were analyzed. The results showed that both groups had achieved complete remission with each induction therapy; however, 5 of 6 patients in group B had long-term remission, while 3 of 4 patients in group A who received bone marrow transplantation relapsed. In conclusion, the new strategy with short-duration combination chemotherapy is safe and useful for BL.
  • Satoko Oka, Kazuo Muroi, Masaki Mori, Tomohiro Matsuyama, Shin-ichiro Fujiwara, Iekuni Oh, Kazuya Sato, Masuzu Ueda, Takahiro Suzuki, Katsutoshi Ozaki, Tadashi Nagai, Keiya Ozawa  Jichi Medical University journal  33-  167  -174  2011/03  [Not refereed][Not invited]
    Detection of minimal residual disease (MRD) in acute myeloblastic leukemia (AML) after bone marrow transplantation is important to predict relapse. It is well known that AML cells show various abnormal antigen expressions. MRD was detected in an AML patient after BMT by flow cytometry measurements of CD34+CD15+CD7+ cells. Subsequently, the patient's AML relapsed.
  • OKABE Hiroshi, SUZUKI Takahiro, OMORI Tsukasa, MORI Masaki, UEHARA Eisuke, HATANO Kaoru, UEDA Masuzu, MATSUYAMA Tomohiro, TOSHIMA Masaki, OZAKI Katsutoshi, NAGAI Tadashi, MUROI Kazuo, OZAWA Keiya  The Japanese journal of clinical hematology  50-  (11)  1626  -1629  2009/11  [Not refereed][Not invited]
  • 蓮江 正賢, 中山 雅之, 森 敬子, 中曽根 悦子, 大門 皇寿, 曽田 学, 小松 有, 佐多 将史, 水品 佳子, 平野 利勝, 中澤 晶子, 鈴木 恵理, 間藤 尚子, 中屋 孝清, 石井 義和, 細野 達也, 山沢 英明, 坂東 政司, 杉山 幸比古, 上田 真寿, 佐藤 一也  気管支学 : 日本気管支研究会雑誌  31-  (6)  2009/11  [Not refereed][Not invited]
  • OKA Satoko, MATSUYAMA Tomohiro, MORI Masaki, FUJIWARA Shin-ichiro, OHO Iekuni, KIKUCHI Satoru, SATO Kazuya, UEDA Masuzu, TOSHIMA Masaki, SUZUKI Takahiro, OZAKI Katsutoshi, NAGAI Tadashi, OZAWA Keiya, MUROI Kazuo  日本輸血細胞治療学会誌 = Japanese journal of transfusion and cell therapy  55-  (5)  589  -595  2009/11  [Not refereed][Not invited]
  • Oka Satoko, Muroi Kazuo, Sato Kazuya, Yamamoto Kawano Chizuru, Ueda Masuzu, Ono Yoko, Matsuyama Tomohiro, Toshima Masaki, Ohmine Ken, Ozaki Katsutoshi, Takatoku Masaaki, Mori Masaki, Nagai Tadashi, Ozawa Keiya  Jichi Medical University journal  30-  173  -180  2007/12  [Not refereed][Not invited]
    Based on histological examinations of endoscopic biopsy specimens, gastrointestinal (GI) tract B-cell lymphoma was diagnosed in 18 patients who had GI tract symptoms as their initial presentation. The affected sites were the stomach, small intestine and large intestine in nine, seven, and two patients, respectively. The histological classifications were as follows: thirteen patients had diffuse large B-cell lymphoma, one had mucosa-associated with lymphoid tissue (MALT) lymphoma, one had mantle cell lymphoma, while three patients had other types. The flow cytometric analysis of biopsy specimens showed restricted light chain expression in the specimens from seven out of nine patients. The specimens from three out of the another seven patients showed a high expression of CD19 or CD20, however, no light chain expression was determined in any of the seven patients because of insufficient cell numbers. Abnormal karyotypes were observed in the specimens from two of five patients. The analyses using histological examinations combined with flow cytometry (FCM) for ordinary endoscopy and biopsy specimens were thus found to have a significant value for the diagnosis of GI tract B-cell lymphoma.
  • MORI Masaki, MUROI Kazuo, MATSUYAMA Tomohiro, OKA Satoko, ONO Yoko, YAMAMOTO Chizuru, UESAWA Mitsuyo, OKABE Hiroshi, MATSU Haruko, TATARA Raine, KIKUCHI Yuji, FUJIWARA Shinichiro, KIKUCHI Satoru, SATO Kazuya, UEDA Masuzu, TOSHIMA Masaki, OZAKI Katsutoshi, TAKATOKU Masaaki, NAGAI Tadashi, OZAWA Keiya  臨床血液 = The Japanese Journal of Clinical Hematology  48-  (8)  624  -631  2007/08  [Not refereed][Not invited]
  • Yamamoto-Kawano Chizuru, Muroi Kazuo, Izumi Tohru, Sato Kazuya, Ueda Masuzu, Matsuyama Tomohiro, Ohmine Ken, Toshima Masaki, Ozaki Katsutoshi, Takatoku Masaaki, Mori Masaki, Nagai Tadashi, Ozawa Keiya  Jichi Medical University journal  29-  105  -113  2006/12  [Not refereed][Not invited]
    Bone marrow of 85 patients with B-cell lymphomas at initial presentation or at relapse was examined simultaneously using both two-color flow cytometry with a CD 19 gate (FCM) and pathologic examination (PTH) including bone marrow aspiration with or without core biopsy. Diffuse large-cell lymphoma (29 patients) and follicular lymphoma (20 patients) were two major subtypes. CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)-based regimens were most frequently used to 47 patients. The median follow-up was 10.5 months. The estimated 2-year overall survival (OS) of the FCM- and PTH-negative group (49 patients), the FCM-positive but PTH-negative group (23 patients) and the FCM-and PTH-positive group (13 patients) was 69±7%, 45±11% and 31±15%, respectively. The estimated 2-year progression-free survival (PFS) of the first, second and third group was 69±7 %, 30±11% and 21±13%, respectively. These results suggest that FCM together with PTH predict the prognosis of B-cell lymphoma. Prospective studies are needed to define the role of flow cytometirc identification of bone marrow lymphoma involvement.

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.